Jiangsu Kanion Pharmaceutical Co., Ltd. operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Jiangsu Kanion Pharmaceutical Co., Ltd. with three other
companies in this sector in China:
Jinling Pharmaceutical Company Limited
sales of 3.19 billion Chinese Renmimbi [US$462.59 million]
of which 68%
was Medicine Manufacture),
Guangdong Taiantang Pharmaceutical Co Ltd
(3.23 billion Chinese Renmimbi [US$468.68 million]
of which 49%
was Medicine Wholesale & Retail), and
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
(3.18 billion Chinese Renmimbi [US$461.21 million]
of which 53%
was Medicine Manufacturing).
During the year ended December of 2017, sales at
Jiangsu Kanion Pharmaceutical Co., Ltd. were 3.27 billion Chinese Renmimbi (US$474.60 million).
increase of 9.1%
versus 2016, when the company's sales were 3.00 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Jiangsu Kanion Pharmaceutical Co., Ltd.
(and since 2012, sales have increased a total of 72%).
Sales of Other Operations saw an increase
that was more than double the company's growth rate: sales were up
220.0% in 2017, from
2.71 million Chinese Renmimbi to 8.69 million Chinese Renmimbi.